1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030

Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030

  • May 2020
  • 100 pages
  • ID: 5893089
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted c-Met Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

C-Met Mutated NSCLC Understanding
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1 , BRAF , C-Met , PD-L1 expression and others. Among all the mutations C-Met accounted for approximately 4% of the total cases of NSCLC.
C-Met is a tyrosine kinase receptor, which is encoded in part by mesenchymal-epidermal transition (MET) exon 14. Mutations in the MET gene can cause increased c-MET signaling and oncogenic stimulation. Although c-MET mutation is rare, it is a targetable driver mutation.
For diagnosis of mutation associated with NSCLC a laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC. The guidelines do not recommend routine screening before treatment decision, there are drugs that can be used in patients who have c-MET mutation or amplification.

Epidemiology Perspective
The C-Met mutated NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The C-Met mutated NSCLC epidemiology data are studied through C-Met mutated NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted C-Met mutated NSCLC epidemiology [segmented as Total Incident Cases of NSCLC, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total NSCLC Cases of Patients by Genetic mutation/Biomarkers, and Treated Patient Pool of NSCLC] scenario of C-Met mutated NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

C-Met Mutated NSCLC Detailed Epidemiology Segmentation
• In histology-specific cases of NSCLC, Adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
• In genetic-mutation specific cases of NSCLC, most number of cases is from PD-L1 followed by KRAS, and EGFR. On the other hand, ROS-1 accounted for least number of cases whereas C-Met accounted for approximately 4% of cases.
• The total incident cases of C-Met mutated NSCLC in the 7MM were found to be 16,658 in 2017 which is expected to grow during the study period, i.e., 2017–2030
• Estimates shows that the highest incident population of C-Met mutated NSCLC is in the United States, followed by Germany, Japan, United Kingdom, and France in 2017.
• The United States accounted for approximately 7,202 cases of C-Met NSCLC in 2017.
• The total cases of C-Met mutated NSCLC in Germany, France, Italy, UK and Japan was found to be around 2,138, 1,508, 1,277, 1,664, and 2,000, respectively in 2017.

Scope of the Report
• The C-Met mutated NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The C-Met mutated NSCLC Report and Model provide an overview of the risk factors and global trends of C-Met mutated NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of C-Met mutated NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of C-Met mutated NSCLC.
• The report provides the segmentation of the NSCLC epidemiology by incident cases of NSCLC patients by histology in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by diagnosed cases of NSCLC patients by stages in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by genetic mutation/biomarkers in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by treated patient pool of NSCLC in the 7MM.

Report Highlights
• 11-Year Forecast of C-Met mutated NSCLC epidemiology
• 7MM Coverage
• Total Incident Cases of NSCLC
• Incident Cases according to segmentation: Histology, Stage, Genetic Mutation/Biomarker
• Treated cases of NSCLC

KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over C-Met mutated NSCLC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to C-Met mutated NSCLC?
• What are the key findings pertaining to the C-Met mutated NSCLC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of C-Met mutated NSCLC across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of C-Met mutated NSCLC?

Reasons to buy
The C-Met mutated NSCLC Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global C-Met mutated NSCLC market
• Quantify patient populations in the global C-Met mutated NSCLC market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for C-Met mutated NSCLC therapeutics in each of the markets covered
• Understand the magnitude of C-Met mutated NSCLC population by its severity
• The C-Met mutated NSCLC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The C-Met mutated NSCLC Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Total cases of C-Met mutated NSCLC in the 7MM was assessed to be 16,658 in 2017, and are expected to increase during the study period. Among the European 5 countries, the Germany had highest incident population of C-Met NSCLC, followed by United Kingdom and France. On the other hand, Spain had the lowest incident population of C-Met NSCLC, in 2017. Furthermore, Japan accounts for about 12% of the total 7MM incident population of C-Met NSCLC (in 2017).
‘Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted c-Met Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

C-Met Mutated NSCLC Understanding
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1 , BRAF , C-Met , PD-L1 expression and others. Among all the mutations C-Met accounted for approximately 4% of the total cases of NSCLC.
C-Met is a tyrosine kinase receptor, which is encoded in part by mesenchymal-epidermal transition (MET) exon 14. Mutations in the MET gene can cause increased c-MET signaling and oncogenic stimulation. Although c-MET mutation is rare, it is a targetable driver mutation.
For diagnosis of mutation associated with NSCLC a laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC. The guidelines do not recommend routine screening before treatment decision, there are drugs that can be used in patients who have c-MET mutation or amplification.

Epidemiology Perspective
The C-Met mutated NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The C-Met mutated NSCLC epidemiology data are studied through C-Met mutated NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted C-Met mutated NSCLC epidemiology [segmented as Total Incident Cases of NSCLC, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total NSCLC Cases of Patients by Genetic mutation/Biomarkers, and Treated Patient Pool of NSCLC] scenario of C-Met mutated NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

C-Met Mutated NSCLC Detailed Epidemiology Segmentation
• In histology-specific cases of NSCLC, Adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
• In genetic-mutation specific cases of NSCLC, most number of cases is from PD-L1 followed by KRAS, and EGFR. On the other hand, ROS-1 accounted for least number of cases whereas C-Met accounted for approximately 4% of cases.
• The total incident cases of C-Met mutated NSCLC in the 7MM were found to be 16,658 in 2017 which is expected to grow during the study period, i.e., 2017–2030
• Estimates shows that the highest incident population of C-Met mutated NSCLC is in the United States, followed by Germany, Japan, United Kingdom, and France in 2017.
• The United States accounted for approximately 7,202 cases of C-Met NSCLC in 2017.
• The total cases of C-Met mutated NSCLC in Germany, France, Italy, UK and Japan was found to be around 2,138, 1,508, 1,277, 1,664, and 2,000, respectively in 2017.

Scope of the Report
• The C-Met mutated NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The C-Met mutated NSCLC Report and Model provide an overview of the risk factors and global trends of C-Met mutated NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of C-Met mutated NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of C-Met mutated NSCLC.
• The report provides the segmentation of the NSCLC epidemiology by incident cases of NSCLC patients by histology in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by diagnosed cases of NSCLC patients by stages in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by genetic mutation/biomarkers in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by treated patient pool of NSCLC in the 7MM.

Report Highlights
• 11-Year Forecast of C-Met mutated NSCLC epidemiology
• 7MM Coverage
• Total Incident Cases of NSCLC
• Incident Cases according to segmentation: Histology, Stage, Genetic Mutation/Biomarker
• Treated cases of NSCLC

KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over C-Met mutated NSCLC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to C-Met mutated NSCLC?
• What are the key findings pertaining to the C-Met mutated NSCLC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of C-Met mutated NSCLC across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of C-Met mutated NSCLC?

Reasons to buy
The C-Met mutated NSCLC Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global C-Met mutated NSCLC market
• Quantify patient populations in the global C-Met mutated NSCLC market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for C-Met mutated NSCLC therapeutics in each of the markets covered
• Understand the magnitude of C-Met mutated NSCLC population by its severity
• The C-Met mutated NSCLC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The C-Met mutated NSCLC Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Total cases of C-Met mutated NSCLC in the 7MM was assessed to be 16,658 in 2017, and are expected to increase during the study period. Among the European 5 countries, the Germany had highest incident population of C-Met NSCLC, followed by United Kingdom and France. On the other hand, Spain had the lowest incident population of C-Met NSCLC, in 2017. Furthermore, Japan accounts for about 12% of the total 7MM incident population of C-Met NSCLC (in 2017).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on